Form 4: Travere Therapeutics Director Sandra Poole Reports Acquisition and Disposal of Shares

Director Sandra Poole reports acquiring shares and disposing of shares of Travere Therapeutics, Inc. common stock on May 15, 2025.

Summary

• On May 15, 2025, Sandra Poole, a director of Travere Therapeutics, Inc., reported acquiring 6,500 shares of common stock at $0 and disposing of 30,000 shares.
• Following these transactions, Poole directly owns 30,000 shares of Travere Therapeutics.
• Poole also acquired options to purchase 19,500 shares of common stock at an exercise price of $21.15, vesting over one year and expiring on May 15, 2035.
• These transactions were reported on a Form 4 filing with the SEC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports transactions without providing explicit positive or negative signals. The disposal of shares could be a slight negative, but without further context, it's difficult to assess the overall impact.

Positives

• The acquisition of stock options could align the director's interests with those of the shareholders.

Negatives

• The disposal of 30,000 shares by a director could be perceived negatively by investors, although the reason for disposal is not stated.

Risks

• The document does not provide context for the disposal of shares, which could lead to speculation and uncertainty among investors.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options suggests a one-year commitment from the director.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Director compensation packages often include stock options to align management's interests with shareholder value.
• The vesting period of one year is a common practice in equity compensation plans.
• Comparing the exercise price of $21.15 to the current market price of Travere Therapeutics stock would provide further insight into the potential value of these options.

Stakeholder Impact

• Shareholders may react to the reported transactions, particularly the disposal of shares.
• The stock options granted could incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

Travere Therapeutics, Sandra Poole, Form 4, stock options, share disposal, director, equity, acquisition